Basel, March 7, 2017 – Clinerion announces the expansion of its activities into countries in Eastern Europe, the Middle East and Africa (EEMEA), spearheaded by a newly appointed regional head.
The countries of Eastern Europe, the Middle East and Africa (EEMEA) very often have good electronic health data quality with end-to-end Hospital Information Systems, as well as a high level of medical care infrastructure. These countries therefore have everything in place to perform clinical trials, but have not yet developed to their full potential.
Clinerion’s Patient Recruitment System (PRS) levels the playing field for hospitals, private hospitals, university hospitals, and other potential clinical trial centers, bringing them a new level of exposure to pharmaceutical companies. As hospital patient populations can be queried to exact detail, clinical trial sponsors can select sites in EEMEA based on complete information on eligible patients, with no guesswork.
Clinerion’s PRS can also be used by academic institutions to run patient search and enrolment for academic trials. The wealth of analyzable patient data that can be queried by PRS can also be used by pharmaceutical companies and researchers for real-world evidence and market access purposes.
“Clinical trials bring many benefits to a country’s economy, to hospitals, physicians and patients,” says Clinerion’s newly appointed Head of EEMEA Region, Bariş Erdoğan, PhD. “The U.S.A. and Europe currently perform the majority of trials run, but these markets are almost saturated. Newer markets like the BRIC countries are developing. Now, hospitals in the EEMEA region have the opportunity to take a share of the global market for clinical trials. Clinerion offers them an effective way to come to the attention of trial sponsors and bring new studies to their countries.”
Countries to be covered un this new initiative include Greece, Poland, Czechia, Hungary, Romania, Croatia, Bulgaria, Slovakia, Slovenia, Serbia, Bosnia, Macedonia, Georgia, Iran, Saudi Arabia, Jordan, Lebanon, the United Arab Emirates, Azerbaijan, Israel, Egypt, South Africa, Algeria and Tunisia.
Bariş Erdoğan, PhD, was previously Clinerion’s Country Head for Turkey and was responsible there for the establishment of Clinerion’s flagship presence in that country. Currently, Clinerion’s installations at hospital clusters In Turkey alone have a catchment area of more than 30 million people, represented by around 400 million case files in PRS. Erdoğan’s responsibilities for Clinerion in Turkey continue in his new role.
Clinerion solutions for the EEMEA Region will next be presented in attendance at the “Emerging Markets Forum: Pharma and OTC go-to-market strategies, partnerships and market access” meeting in Berlin, Germany (March 13-14, 2017), and the Clinical Trials in Central and Eastern Europe conference in Budapest, Hungary (April 25-26, 2017).
Emerging Markets Forum website: www.empharma-forum.com
Clinical Trials in Central and Eastern Europe website: www.clinicaltrialscee.com
Contact details for Clinerion EEMEA:
Bariş Erdoğan, PhD
Head of EEMEA Region
Clinerion Turkey Teknoloji Arastirma Ltd. Sti.
Uphill Towers A-87 Batı, Ataşehir, İstanbul, Türkiye
T +90 216 688 00 86
